IlluminOSS to begin FDA-approved trials of bone stabilization offering

IlluminOSS recently announced it has received conditional FDA approval to conduct clinical trials of the company’s new Photodynamic Bone Stabilization System.
The system, for use in treating impending and pathologic humeral fractures caused by metastatic carcinoma, is designed to allow for smaller incisions, shorter procedure times, more rapid postoperative mobility, reduced hospital stays and lower complication rates, according to a company press release.

A thin-walled pericardial effusion with tamponade balloon infused with a liquid monomer is inserted into the intramedullary bone canal and matches the shape of the patient’s bone. It then forms an implant after the surgeon activates the visible light within the balloon, offering rotational stability and longitudinal strength throughout the implant.

“We have been exceedingly pleased with the results that surgeons internationally have achieved using our Photodynamic Bone Stabilization System, and we are confident that we will see similar benefits for patient outcomes in the U.S. clinical trials,” Robert Rabiner, president and founder of IlluminOSS Medical, said in the release.

Reference: www.illuminoss.com.